Opendata, web and dolomites

BITCAT SIGNED

Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BITCAT project word cloud

Explore the words cloud of the BITCAT project. It provides you a very rough idea of what is the project "BITCAT" about.

systemic    ctla4    rna    mechanism    suppression    escape    genetics    pto    evading    university    either    proper    advantageous    propagating    german    researcher    modulate    liposomal    immunotherapy    antibodies    expression    employment    successful    efficacy    vaccines    practical    nanoparticles    fraunhofer    immune    immunology    pd    environment    anti    advantages    soluble    considerable    ex    world    antisense    oligonucleotides    charmingly    checkpoint    arose    tumours    career    protein    immunity    receptor    l1    designed    reduce    mediated    advantage    interests    polyethylenimine    antagonistic    candidates    canadian    society    completely    exon    oncology    cell    special    vitro    isoforms    cancer    good    potentially    tumour    class    toxicity    tested    block    utilized    vivo    surface    mcmaster    scientific    drugs    clinical    tissue    prolific    bioavailability    area    skipping    technique    immunotherapeutics    inhibition    renowned    competitive    genes    induce    models    demonstrated    polycationic    therapy    health   

Project "BITCAT" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 243˙352 €
 EC max contribution 243˙352 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-05-08   to  2020-05-07

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 243˙352.00
2    MCMASTER UNIVERSITY CA (HAMILTON) partner 0.00

Map

 Project objective

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity. Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed. To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms. To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution. Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BITCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BITCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More  

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

DIGILEAD (2020)

Digital leadership, well-being and performance in organizations

Read More